Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Tan on the Rationale for Evaluating an Adaptive Immunotherapy Strategy in Previously Untreated RCC

August 1st 2025

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma

August 1st 2025

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

VT3989 Receives FDA Orphan Drug Designation for Mesothelioma

August 1st 2025

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Minimally Invasive Surgery and Multidisciplinary Collaboration Improve Recovery Time in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the evolution of thoracic surgical oncology, along with newer minimally invasive approaches to surgery in lung cancer.

Dr Riedel on the Role of the Multidisciplinary Team in PEComa Management

July 31st 2025

Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

July 31st 2025

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Dr Dietrich on the Efficacy and Safety of Taletrectinib in ROS1+ NSCLC

July 31st 2025

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer

July 31st 2025

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.

Biomarkers May Inform Potential Role for Ipilimumab/Nivolumab in Untreated Metastatic Urothelial Cancer After Missing OS End Point

July 30th 2025

Guru P. Sonpavde, MD, discusses the role of ipilimumab/nivolumab after negative trial results in managing advanced urothelial cancer.

Dr Sen on the Role of Immunotherapy in SCLC

July 30th 2025

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Additive IL-6 Inhibition Improves ICI-Related Response Rates and Safety in Advanced Melanoma

July 30th 2025

Janice Mehnert, MD, discusses the rationale for adding IL-6 inhibition to an ICI backbone and data with sarilumab plus ICIs in advanced melanoma.

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Novel LYN/BTK Dual Inhibitor Yields Durable Responses in Heavily Pretreated CLL/SLL

July 29th 2025

DZD8586 was active with a tolerable safety profile in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Efforts to Yield Greater OS Benefit With EGFR TKIs Continue in Early-Stage EGFR+ NSCLC

July 28th 2025

Roy S. Herbst, MD, PhD, highlights the evolution of EGFR TKIs and the need for treatments improving DFS and OS outcomes in EGFR-mutant NSCLC.

How Multiomics and Artificial Intelligence Are Transforming Localized NSCLC: A Deep Dive

July 28th 2025

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Vimseltinib Earns Positive CHMP Recommendation for TGCT

July 28th 2025

The EMA’s CHMP recommended the approval of vimseltinib for symptomatic tenosynovial giant cell tumor.

FDA Grants Priority Review to Perioperative Durvalumab in Resectable Gastric/GEJ Cancer

July 28th 2025

Durvalumab received FDA priority review and breakthrough therapy designation for resectable gastric and GEJ adenocarcinoma.

Perioperative Tislelizumab Receives Positive CHMP Opinion for High-Risk Resectable NSCLC

July 28th 2025

Perioperative tislelizumab received a positive CHMP opinion for resectable non–small cell lung cancer at high risk of recurrence.

Immunotherapy Sequencing Must Be Personalized During Therapy Selection for Metastatic RCC

July 28th 2025

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.